Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 633-644

  Cotter, Murray A ^c   Robertson, Erle S ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c NONE

Author keywords

B lymphocytes; Epstein Barr virus; Herpes simplex virus; Lymphoblastoid cell lines

Indexed keywords

DNA; DNA FRAGMENT; NUCLEAR PROTEIN;

B LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC ANALYSIS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; LYMPHOBLASTOID CELL; MOLECULAR CLONING; MOLECULAR GENETICS; REVIEW;

EID: 0032720040     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Roizman B: Herpesviridae Fields Virology. Fields K, Howley P (Eds), Lippincott-Raven, Philadelphia, New York, 3rd edition (1996) 2:2221.
2. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS: Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer (1978) 42:2379-2391.
3. Henle W, Henle G, Lennette ET: The Epstein-Barr virus. Sci Am (1979) 241:48-59.
4. Kieff E (Ed): Epstein-Barr Virus and its replication. Lippincott-Raven, Philadelphia, 3rd edition (1996) 2.
5. Rickinson A, Kieff E (Eds): Epstein-Barr Virus. Lippincott-Raven, Philadelphia, 3rd edition (1996) 2.
6. Baer R, Banker A, Biggin M, Deininger P, Farrell P, Gibson T, Hatful G, Satchwell S, Seguin C, Tuffnell P, Barrell B: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 310:207-211.
7. Farrell P: Epstein-Barr Virus. Cold Spring Harbor Laboratory, Cold Spring Harbor (1993) 1.
8. Sugden B: Epstein-Barr virus. Synthesis for a complex role. Nature (1989) 339:179-180.
9. Sugden B: An intricate route to immortality. Cell (1989) 57:5-7.
10. Kieff E, Izumi K, Longnecker R, Mannick J, Miller C, Robertson E, Swaminathan S, Tomkinson B, Tong X, Yalamanchili R: Specifically mutated Epstein-Barr Virus recombinants: Defining the minimal transforming genome for primary B-cell transformation. In: Viruses and Cancer. Minson A, Neil J, McRae M (Eds), Cambridge University Press, Cambridge, (1994) 1:123-147.
11. Tomkinson B, Robertson E, Yalamanchili R, Longnecker R, Kieff E: Epstein-Barr virus recombinants from overlapping cosmid fragments. J virol (1993) 67:7298-7306.
12. Hammerschmidt W, Sugden B: Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell (1988) 55:427-433.
13. Marchini A, Kieff E, Longnecker R: Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: a method useful for analysis of genes essential for transformation. J Virol (1993) 67:606-609.
14. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A: Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBKA-3C genes. J Virol (1990) 64:4084-4092.
15. Cohen JI, Wang F, Kieff E: Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 65:2545-2554.
16. Cohen JI, Wang F, Mannick J, Kieff E: Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA (1989) 86:9558-9562.
17. Hammerschmidt W, Sugden B: Genetic analysis of immortalizing functions of Epstein-Barr virus in human B-lymphocytes. Nature (1989) 340:393-397.
18. Tomkinson B, Kieff E: Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA-3 genes in place of type 2 has no effect on in vitro infection. J Virol (1992) 66:780-789.
19. Robertson ES, Tomkinson B, Kieff E: An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B-lymphocytes in vitro. J Virol (1994) 68:1449-1458.
20. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W: Immortalization of human B-lrymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 69:231-238.
21. Robertson E, Kieff E: Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J Virol (1995) 69:983-993.
22. Lee MA, Kim OJ, Yates JL: Targeted gene disruption in Epstein-Barr virus. Virology (1992) 189:253-265.
23. Lee MA, Yates JL: BHRF1 of Epstein-Barr virus, which is homologous to human proto-oncogene bcl2, is not essential for transformation of B-cells or for virus replication in vitro. J Virol (1992) 66:1899-1906.
24. Marchini A, Longnecker R. Kieff E: Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants. J Virol (1992) 66:4972-4981.
25. Marchini A, Tomkinson B, Cohen JI, Kieff E: BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 65:5991-6000.
26. Wang F, Kikutani H, Tsang SF, Kishimoto T, Kieff E: Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element J Virol (1991) 65:4101-4106.
27. Sugden B, Marsh K, Yates J: A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol (1985) 5:410-413.
28. Lindahl T, Adams A, Bjursell G, Bomkamm GW, Kaschka-Dierich C, Jehn U: Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol (1976) 102:511-130.
29. Lindahl T, Adams A, Andersson-Anvret M, Falk L: Integration of Epstein-Barr virus DNA. IARC Sci Publ (1978) 24:113-123.
30. Kwong AD, Frenkel N: The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology (1985) 142:421-425.
31. Robertson ES, Ooka T, Kieff ED: Epstein-Barr virus vectors for gene delivery to B-lymphocytes. Proc Natl Acad Sci USA (1996) 93:11334-11340.
32. Wang F, Li X, Annis B, Faustman DL: Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells. Hum Gene Ther (1995) 6:1005-1017.
33. Wang S, Vos JM: A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol (1996) 70:8422-8430.
34. Banerjee S, Livanos E, Vos JM: Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nature Med (1995) 1:1303-1308.
35. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E: The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 65:6826-6837.
36. Harada S, Kieff E: Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol (1997) 71:6611-6618.
37. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 266:1865-1869.
38. Tong X, Drapkin R, Reinberg D, Kieff E: The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci USA (1995) 92:3259-3263.
39. Tong X, Yalamanchili R, Harada S, Kieff E: The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J Virol (1994) 68:6188-6197.
40. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E: The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA (1994) 91:7568-7572.
41. Hamaguchi Y, Yamamoto Y, Iwanari H, Maruyama S, Furukawa T, Matsunami N, Honjo T: Biochemical and immunological characterization of the DNA binding protein (RBP-Jκ) to mouse Jκ recombination signal sequence. J Biochem 112:314-320.
42. Henkel T, Ling PD, Hayward SD, Peterson MG: Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 265:92-95.
43. Ling PD, Rawlins DR, Hayward SD: The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA (1993) 90:9237-9241.
44. Yalamanchili R, Tong X, Grossman S, Johannsen E, Mosialos G, Kieff E: Genetic and biochemical evidence that EBNA-2 interaction with a 63-kDa cellular GTG-binding protein is essential for B-lymphocyte growth transformation by EBV. Virology (1994) 204:634-641.
45. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E: Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 64:3407-3416.
46. Swaminathan S: Characterization of Epstein-Barr virus recombinants with deletions of the BamHI C promoter. Virology (1996) 217:532-541.
47. Swaminathan S, Tomkinson B, Kieff E: Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci USA (1991) 88:1546-1550.
48. Tomkinson B, Robertson E, Kieff E: Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 67:2014-2025.
49. Tomkinson B, Kieff E: Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 66:2893-2903.
50. Kempkes B, Pich D, Zeidler R, Hammerschmidt W: Immortalization of human primary B-lymphocytes in vitro with DNA. Proc Natl Acad Sci USA (1995) 92:5875-5879.
51. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, Tomkinson B, Kieff E: Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 69:3108-3116.
52. Longnecker R: Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2. Leukemia (1994) 8(Suppl 1):S46-S50.
53. Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E: The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol (1993) 67:2006-2013.
54. Longnecker R, Miller CL, Tomkinson B, Miao XQ, Kieff E: Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol (1993) 67:5068-5074.
55. Fennewald S, Van Santen V, Kieff E: The nucleotide sequence of a messenger RNA transcribed in latent growth transforming virus infection indicates that it may encode a membrane protein. J Virol (1984) 51:411-419.
56. Izumi KM, Kaye KM, Kieff ED: The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B-lymphocyte growth transformation. Proc Natl Acad Sci USA (1997) 94:1447-1452.
57. Izumi KM, Kaye KM, Kieff ED: Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. J Virol (1994) 68:4369-4376.
58. Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B-lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA (1997) 94:12592-12597.
59. Kaye KM, Izumi KM, Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA (1993) 90:9150-9154.
60. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 80:389-399.
61. Decaussin G, Leclerc V, Ooka T: The lytic cycle of Epstein-Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame. J Virol (1995) 69:7309-7314.
62. Delecluse H, Pich D, Hilsendegen T, Baum C, Hammerschmidt W: A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci USA (1999) 96:5188-5193.
63. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC: Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis (1994) 170:1100-1109.
64. Speck PG, Efstathiou S, Minson AC: In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector. J Gen Virol (1996) 77:2563-2568.
65. Cancer gene therapy - First International Conference, Hammersmith Hospital, London, UK. 8-9 July (1999).
66. Alt M, Fleckenstein B, Grassmann R: A pair of selectable herpesvirus for simultaneous gene expression in human lymphoid cells. Gene (1991) 102:265-269.
67. Coffin RS, MacLean AR, Latchman DS, Brown SM: Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther (1996) 3:886-891.
68. Fraefel C, Song S, Um F, Lang P, Yu L, Wang Y, Wild P, Geller AI: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 70:7190-7197.
69. Lim F, Hartley D, Starr P, Lang P, Song S, Yu L, Wang Y. Geller AI: Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques (1996) 20:460-469.
70. During MJ, Naegele JR, O'Malley KL, Geller AI: Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science (1994) 266:1399-1403.
71. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, Ramig L, Thompson L, Mazzoitta J, Huang S, Grafton S, Brooks D, Sawle G, Schroter G, Ansari A: Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New Engl J Med (1992) 327:1549-1555.
72. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, Bunney B, Elsworth J, Kier L, Makuch R, Hoffer P, Redmond E: Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. New Engl J Med (1992) 327:1541-1548.
73. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Bjorklund A, Lindvall O, Langsten JW: Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl J Med (1992) 327:1556-1563.
74. DeLuca NA, McCarthy AM, Schaffer PA: Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 56:558-570.